Production and purification of melanoma gp100 antigen and polyclonal antibodies

Protein Expression and Purification

Volumn 34, Issue 2, 2004, Pages 183-189

  Gelbart, Y ^a   Frankenburg, S ^b   Pinchasov, Y ^c   Krispel, S ^a   Eliahu, D ^a   Drize, O ^b   Morag, E ^c   Bartfeld, D ^a   Lotem, M ^b   Peretz, T ^b   Pitcovski, J ^a,b  

^a MIGAL GALILEE TECHNOLOGY CENTER   (Israel)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^c YAMIT   (Israel)

Author keywords

Antibodies; gp100; Melanoma

Indexed keywords

ESCHERICHIA COLI; GALLUS GALLUS;

EID: 12144286025     PISSN: 10465928     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pep.2003.12.006     Document Type: Article

References (15)

1. M. Lotem, E. Shiloni, A. Ingber, T. Peretz, Active specific immunotherapy of malignant melanoma, Harefuah 133 (1997) 122-126.
2. S.A. Rosenberg, A new era for cancer immunotherapy based on the genes that encode cancer antigens, Immunity 10 (1999) 281-287.
3. Y.T. Chen, L.J. Old, Cancer-testis antigens: targets for cancer immunotherapy, Cancer J. Sci. Am. 5 (1999) 16-17.
4. Y. Sixon, K. Kittlesen, L. Craig, L. Darrow, Dendritic cells with a vaccinia vector carrying the human gp100 gene simultaneously present multiply specificities and elicit high affinity T cells reactive to multiply epitopes and restricted by HLA-A2 and A3, J. Immunol. 164 (2000) 4204-4211.
5. W.G. Hawkins, J.S. Gold, R. Dyall, J.D. Wolchok, A. Hoos, W.B. Bowne, R. Srinivasan, A.N. Houghton, J.J. Lewis, Immunization with DNA coding for gp100 results CD4 T-cell independent antitumor immunity, Surgery 128 (2000) 273-280.
6. M. Nawrath, J. Pavlovic, K. Moelling, Synergistic effect of a combined DNA and peptide vaccine against gplOO in a malignant melanoma mouse model, J. Mol. Med. 79 (2001) 133-142.
7. S.N. Wagner, C. Wagner, T.K. Weimann, R. Kutil, Intracutaneous genetic immunization with autologous melanoma associated antigen Pme117/go100 induces T-cell mediated tumor protection in vivo, J. Invest. Dermatol. 115 (2000) 1082-1087.
8. J. Banchereau, A.K. Palucka, M. Dhodapkar, S. Burkeholder, N. Taquet, Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine, Cancer Res. 61 (2001) 6451-6458.
9. R. Lau, F. Wang, G. Jeffery, V. Marty, J. Kuniyoshi, E. Bade, M.E. Ryback, Phase I trial of intravenous peptide-pulsed dendritic cells in patients with metastatic melanoma, J. Immunother. 24 (2001) 66-78.
10. C. Rieser, G. Bock, H. Klocker, G. Bartsch, M. Thurnher, Prostaglandin E2 and tumor necrosis factor alpha cooperate to activate human dendritic cells: synergistic activation of interleukin 12 production, J. Exp. Med. 186 (1997) 1603-1608.
11. H. Jonuleit, U. Kuhn, G. Muller, K. Steinbrink, L. Paragnik, E. Schmitt, J. Knop, A.H. Enk, Proinflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum free conditions, Eur. J. Immunol. 27 (1997) 3135-3142.
12. R. Lapointe, R.E. Royal, M.E. Reeves, I. Altomare, P.F. Robbins, P. Hwu, Retrovirally transduced human dendritic cells can generate T cells recognizing multiple MHC class I and class II epitopes from the melanoma antigen glycoprotein 100, J. Immunol. 167 (2001) 4758-4764.
13. Y. Wan, P. Emtage, Q. Zhu, R. Foley, A. Pilon, J. Roberts, J. Gauldie, Enhanced immune response to the melanoma antigen gplOO using recombinant adenovirus-transduced dendritic cells, Cell Immunol. 198 (1999) 131-138.
14. A.I. Riker, U.S. Kammula, M.C. Panelli, E. Wang, G.A. Ohnmacht, S.M. Steinberg, S.A. Rosenberg, F.M. Marincola, Threshold levels of gene expression of the melanoma antigen gp100 correlate with tumor cell recognition by cytotoxic T lymphocytes, Int. J. Cancer 86 (2000) 818-826.
15. B. Cochlovius, M. Linnebacher, M. Zewe-Welschof, M. Zoller, Recombinant gp100 protein presented by dendritic cells elicits a T-helper-cell response in vitro and in vivo, Int. J. Cancer 83 (1999) 547-554.